STOCK TITAN

[Form 4] Sight Sciences, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

On 07/02/2025, Sight Sciences (SGHT) Chief Commercial Officer Matthew Link filed a Form 4 reporting the sale of 4,889 common shares at an average price of $4.098 per share.

The filing notes the shares were sold solely to satisfy the executive’s tax liability related to the vesting of restricted stock units. Following the transaction, Link continues to hold 832,293 shares of SGHT, retaining more than 99% of his previous direct ownership. No derivative securities were acquired or disposed of.

The sale represents a routine, low-volume insider disposition—approximately 0.6% of the executive’s holdings—and is unlikely to materially affect investor sentiment or the company’s share-price outlook.

Il 07/02/2025, Matthew Link, Chief Commercial Officer di Sight Sciences (SGHT), ha presentato un Modulo 4 segnalando la vendita di 4.889 azioni ordinarie a un prezzo medio di $4,098 per azione.

Il documento specifica che le azioni sono state vendute esclusivamente per coprire l'obbligo fiscale derivante dalla maturazione delle unità azionarie vincolate. Dopo la transazione, Link detiene ancora 832.293 azioni di SGHT, mantenendo oltre il 99% della sua precedente partecipazione diretta. Non sono stati acquisiti né ceduti strumenti derivati.

La vendita rappresenta una normale operazione interna a basso volume—circa lo 0,6% delle partecipazioni dell'esecutivo—e difficilmente influenzerà in modo significativo il sentiment degli investitori o le prospettive del prezzo delle azioni della società.

El 07/02/2025, Matthew Link, Director Comercial de Sight Sciences (SGHT), presentó un Formulario 4 reportando la venta de 4.889 acciones comunes a un precio promedio de $4.098 por acción.

El documento señala que las acciones se vendieron únicamente para cubrir la obligación fiscal del ejecutivo relacionada con la consolidación de unidades restringidas de acciones. Tras la transacción, Link sigue poseyendo 832.293 acciones de SGHT, conservando más del 99% de su propiedad directa anterior. No se adquirieron ni vendieron valores derivados.

La venta representa una disposición interna rutinaria y de bajo volumen—aproximadamente el 0,6% de las participaciones del ejecutivo—y es poco probable que afecte significativamente el sentimiento de los inversores o las perspectivas del precio de las acciones de la empresa.

2025년 2월 7일, Sight Sciences(SGHT)의 최고상업책임자 매튜 링크는 4,889주의 보통주를 주당 평균 4.098달러에 매도한 내용을 신고하는 Form 4를 제출했습니다.

신고서에는 해당 주식이 제한 주식 단위의 권리 확정에 따른 세금 부담을 충당하기 위해서만 매도되었음이 명시되어 있습니다. 거래 후에도 링크는 여전히 SGHT 주식 832,293주를 보유하고 있으며, 이전 직접 소유 지분의 99% 이상을 유지하고 있습니다. 파생 증권의 취득이나 처분은 없었습니다.

이번 매도는 경영진 보유 주식의 약 0.6%에 해당하는 일상적이고 소규모 내부자 거래로, 투자자 심리나 회사 주가 전망에 큰 영향을 미칠 가능성은 낮습니다.

Le 07/02/2025, Matthew Link, directeur commercial de Sight Sciences (SGHT), a déposé un formulaire 4 signalant la vente de 4 889 actions ordinaires à un prix moyen de 4,098 $ par action.

Le document précise que les actions ont été vendues uniquement pour couvrir l'obligation fiscale liée à l'acquisition des unités d'actions restreintes. Après la transaction, Link détient toujours 832 293 actions de SGHT, conservant plus de 99 % de sa participation directe précédente. Aucun titre dérivé n'a été acquis ou cédé.

Cette vente représente une cession interne habituelle à faible volume—environ 0,6 % des avoirs de l'exécutif—et il est peu probable qu'elle affecte de manière significative le sentiment des investisseurs ou les perspectives du cours de l'action de la société.

Am 07.02.2025 reichte Matthew Link, Chief Commercial Officer von Sight Sciences (SGHT), ein Formular 4 ein, in dem der Verkauf von 4.889 Stammaktien zu einem durchschnittlichen Preis von 4,098 $ pro Aktie gemeldet wurde.

In der Meldung wird angegeben, dass die Aktien ausschließlich verkauft wurden, um die Steuerverpflichtung des Geschäftsführers im Zusammenhang mit der Vesting von Restricted Stock Units zu erfüllen. Nach der Transaktion hält Link weiterhin 832.293 Aktien von SGHT und behält damit mehr als 99 % seines vorherigen direkten Anteils. Es wurden keine Derivate erworben oder veräußert.

Der Verkauf stellt eine routinemäßige, volumenarme Insider-Transaktion dar—etwa 0,6 % der Beteiligungen des Geschäftsführers—und wird voraussichtlich die Anlegerstimmung oder die Kursentwicklung der Aktie nicht wesentlich beeinflussen.

Positive
  • Executive retains 832,293 shares, maintaining substantial alignment with shareholders.
Negative
  • Insider sale reported, though small in size and tax-related.

Insights

TL;DR: Tax-related sale of 4,889 shares is immaterial; ownership largely unchanged—neutral signal.

The Form 4 discloses a small disposition by CCO Matthew Link at $4.098 per share to cover withholding taxes on vested RSUs. The amount sold equals roughly 0.6% of his 837k-share stake, leaving him with 832,293 shares. With no derivative activity and an explicit tax-settlement explanation, the transaction appears administrative rather than indicative of negative insider sentiment. Consequently, the event should have minimal market impact and does not alter the investment thesis for SGHT.

Il 07/02/2025, Matthew Link, Chief Commercial Officer di Sight Sciences (SGHT), ha presentato un Modulo 4 segnalando la vendita di 4.889 azioni ordinarie a un prezzo medio di $4,098 per azione.

Il documento specifica che le azioni sono state vendute esclusivamente per coprire l'obbligo fiscale derivante dalla maturazione delle unità azionarie vincolate. Dopo la transazione, Link detiene ancora 832.293 azioni di SGHT, mantenendo oltre il 99% della sua precedente partecipazione diretta. Non sono stati acquisiti né ceduti strumenti derivati.

La vendita rappresenta una normale operazione interna a basso volume—circa lo 0,6% delle partecipazioni dell'esecutivo—e difficilmente influenzerà in modo significativo il sentiment degli investitori o le prospettive del prezzo delle azioni della società.

El 07/02/2025, Matthew Link, Director Comercial de Sight Sciences (SGHT), presentó un Formulario 4 reportando la venta de 4.889 acciones comunes a un precio promedio de $4.098 por acción.

El documento señala que las acciones se vendieron únicamente para cubrir la obligación fiscal del ejecutivo relacionada con la consolidación de unidades restringidas de acciones. Tras la transacción, Link sigue poseyendo 832.293 acciones de SGHT, conservando más del 99% de su propiedad directa anterior. No se adquirieron ni vendieron valores derivados.

La venta representa una disposición interna rutinaria y de bajo volumen—aproximadamente el 0,6% de las participaciones del ejecutivo—y es poco probable que afecte significativamente el sentimiento de los inversores o las perspectivas del precio de las acciones de la empresa.

2025년 2월 7일, Sight Sciences(SGHT)의 최고상업책임자 매튜 링크는 4,889주의 보통주를 주당 평균 4.098달러에 매도한 내용을 신고하는 Form 4를 제출했습니다.

신고서에는 해당 주식이 제한 주식 단위의 권리 확정에 따른 세금 부담을 충당하기 위해서만 매도되었음이 명시되어 있습니다. 거래 후에도 링크는 여전히 SGHT 주식 832,293주를 보유하고 있으며, 이전 직접 소유 지분의 99% 이상을 유지하고 있습니다. 파생 증권의 취득이나 처분은 없었습니다.

이번 매도는 경영진 보유 주식의 약 0.6%에 해당하는 일상적이고 소규모 내부자 거래로, 투자자 심리나 회사 주가 전망에 큰 영향을 미칠 가능성은 낮습니다.

Le 07/02/2025, Matthew Link, directeur commercial de Sight Sciences (SGHT), a déposé un formulaire 4 signalant la vente de 4 889 actions ordinaires à un prix moyen de 4,098 $ par action.

Le document précise que les actions ont été vendues uniquement pour couvrir l'obligation fiscale liée à l'acquisition des unités d'actions restreintes. Après la transaction, Link détient toujours 832 293 actions de SGHT, conservant plus de 99 % de sa participation directe précédente. Aucun titre dérivé n'a été acquis ou cédé.

Cette vente représente une cession interne habituelle à faible volume—environ 0,6 % des avoirs de l'exécutif—et il est peu probable qu'elle affecte de manière significative le sentiment des investisseurs ou les perspectives du cours de l'action de la société.

Am 07.02.2025 reichte Matthew Link, Chief Commercial Officer von Sight Sciences (SGHT), ein Formular 4 ein, in dem der Verkauf von 4.889 Stammaktien zu einem durchschnittlichen Preis von 4,098 $ pro Aktie gemeldet wurde.

In der Meldung wird angegeben, dass die Aktien ausschließlich verkauft wurden, um die Steuerverpflichtung des Geschäftsführers im Zusammenhang mit der Vesting von Restricted Stock Units zu erfüllen. Nach der Transaktion hält Link weiterhin 832.293 Aktien von SGHT und behält damit mehr als 99 % seines vorherigen direkten Anteils. Es wurden keine Derivate erworben oder veräußert.

Der Verkauf stellt eine routinemäßige, volumenarme Insider-Transaktion dar—etwa 0,6 % der Beteiligungen des Geschäftsführers—und wird voraussichtlich die Anlegerstimmung oder die Kursentwicklung der Aktie nicht wesentlich beeinflussen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Link Matthew

(Last) (First) (Middle)
C/O SIGHT SCIENCES, INC.
4040 CAMPBELL AVE., SUITE 100

(Street)
MENLO PARK CA 94025

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Sight Sciences, Inc. [ SGHT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Commercial Officer
3. Date of Earliest Transaction (Month/Day/Year)
07/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/02/2025 S 4,889(1) D $4.098 832,293 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units.
/s/ Jeremy Hayden, Attorney-in-Fact for Matthew Link 07/07/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many SGHT shares did Matthew Link sell on 07/02/2025?

He sold 4,889 common shares.

What was the sale price of the SGHT shares in the Form 4?

The shares were sold at an average price of $4.098 each.

Why did the Chief Commercial Officer sell SGHT shares?

The filing states the sale was to cover tax liabilities from vested restricted stock units.

How many SGHT shares does Matthew Link own after the sale?

He directly owns 832,293 shares following the transaction.

Does the Form 4 report any derivative security transactions?

No, no derivative securities were acquired or disposed of.

What percentage of his holdings did the CCO sell?

The 4,889 shares represent approximately 0.6% of his direct ownership.
Sight Sciences, Inc.

NASDAQ:SGHT

SGHT Rankings

SGHT Latest News

SGHT Latest SEC Filings

SGHT Stock Data

183.28M
40.79M
20.6%
54.74%
3.04%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MENLO PARK